Aviso Financial Inc. Purchases 5,310 Shares of ResMed Inc. (NYSE:RMD)

Aviso Financial Inc. lifted its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 184,588 shares of the medical equipment provider's stock after buying an additional 5,310 shares during the quarter. ResMed comprises approximately 2.1% of Aviso Financial Inc.'s investment portfolio, making the stock its 17th largest holding. Aviso Financial Inc. owned about 0.13% of ResMed worth $42,213,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of RMD. Geode Capital Management LLC boosted its position in shares of ResMed by 10.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider's stock worth $939,114,000 after purchasing an additional 380,383 shares in the last quarter. Los Angeles Capital Management LLC increased its position in ResMed by 60.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 668,908 shares of the medical equipment provider's stock valued at $152,973,000 after buying an additional 250,746 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec raised its stake in ResMed by 726.3% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 283,801 shares of the medical equipment provider's stock worth $69,281,000 after buying an additional 249,454 shares during the period. Proficio Capital Partners LLC bought a new position in ResMed in the fourth quarter worth approximately $50,364,000. Finally, Nordea Investment Management AB grew its stake in ResMed by 92.7% in the fourth quarter. Nordea Investment Management AB now owns 448,151 shares of the medical equipment provider's stock valued at $103,214,000 after acquiring an additional 215,561 shares during the period. Institutional investors own 54.98% of the company's stock.

Remove Ads

ResMed Stock Performance

ResMed stock traded down $4.67 during mid-day trading on Tuesday, reaching $220.07. 710,566 shares of the company's stock were exchanged, compared to its average volume of 963,267. The firm has a market capitalization of $32.32 billion, a PE ratio of 25.98, a P/E/G ratio of 1.53 and a beta of 0.74. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The business's fifty day simple moving average is $236.09 and its 200 day simple moving average is $239.66. ResMed Inc. has a one year low of $172.19 and a one year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, sell-side analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed's dividend payout ratio is currently 25.03%.

Insider Transactions at ResMed

In other news, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the completion of the transaction, the chief executive officer now owns 455,472 shares in the company, valued at approximately $107,842,105.44. This represents a 1.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the completion of the transaction, the insider now owns 9,725 shares of the company's stock, valued at $2,289,265. This represents a 48.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,940 shares of company stock worth $9,164,385 in the last quarter. Insiders own 0.71% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on RMD shares. Stifel Nicolaus lowered their target price on ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a research report on Wednesday, March 5th. Piper Sandler upped their price objective on shares of ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a report on Friday, January 31st. KeyCorp lifted their price objective on shares of ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a report on Friday, January 31st. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, ResMed presently has a consensus rating of "Moderate Buy" and an average price target of $243.82.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.